Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ESOMEPRAZOLE

All products: not a benefit

Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable

  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit
  • Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
  • Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, Not a benefit
  • Pantoprazole (Pantoloc): limited Use 293, 295, 297, 401, 402, Not a benefit
  • Dexlansoprazole (Dexilant): not a benefit

7 more in the class list below

Myl-Esomeprazole · DIN 02479419 · 20mg · DR tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Myl-Esomeprazole · DIN 02479419 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2020-04-20 · brand MYL-ESOMEPRAZOLE · ATC A02BC05 ESOMEPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97006 · Verify on the e-Formulary ↗ (DIN 02479419)

Source record
DIN 02479419: Myl-Esomeprazole Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 564000110; group id 677; item number 1692; lccId None; manufacturer id MYL Source form: DR Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.8690; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479419 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97006
Interchangeable products
Apo-Esomeprazole · DIN 02339099 · not recorded Esomeprazole · DIN 02442493 · not recorded Esomeprazole · DIN 02520699 · not recorded Esomeprazole · DIN 02535335 · not recorded M-Esomeprazole · DIN 02520109 · not recorded Nexium · DIN 02244521 · not recorded PMSC-Esomeprazole DR · DIN 02528479 · not recorded Ran-Esomeprazole · DIN 02423979 · not recorded Sandoz Esomeprazole · DIN 02460920 · not recorded Teva-Esomeprazole · DIN 02423855 · not recorded
Shortage status: resolved shortage (ended 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479419
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS NEXIUM (esomeprazole delayed release tablets or esomeprazole delayed release granules) is indicated in adults (18 years of age and above) for treatment of conditions where a reduction in gastric acid secretion is required such as:  reflux esophagitis  maintenance treatment of patients with reflux esophagitis  nonerosive reflux disease (NERD) (i.e. heartburn and regurgitation)  healing of NSAID*-associated gastric ulcers  reduction of risk of NSAID-associated gastric ulcers  treatment of pathological hypersecretory conditions, including Zollinger -Ellison syndrome  Helicobacter pylori (H. pylori) eradication NEXIUM, in combination with clarithromycin and amoxicillin, is indicated for the treatment of patients with duodenal ulcer disease associated with Helicobacter pylori infection to eradicate the H. pylori and heal ulcers. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. *Note: Superiority of NEXIUM over ranitidine 150 mg BID with the use of non -selective NSAIDs was demonstrated. Superiority was not established with the use of COX-2 selective NSAIDs alone due to the small number of… https://pdf.hres.ca/dpd_pm/00062936.PDF PM date: SEP 16, 2021 Source product: NEXIUM - 20MG; DIN 02244521; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Myl-Esomeprazole: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026